Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole

被引:2
作者
Chapman, Judith-Anne W. [1 ]
Bayani, Jane [2 ,3 ]
Sengupta, Sandip [4 ]
Bartlett, John M. S. [5 ]
Piper, Tammy [5 ]
Quintayo, Mary Anne [2 ]
Virk, Shakeel [6 ]
Goss, Paul E. [7 ]
Ingle, James N. [8 ]
Ellis, Matthew J. [9 ]
Sledge, George W. [10 ]
Budd, G. Thomas [11 ]
Rabaglio, Manuela [12 ]
Ansari, Rafat H. [13 ]
Tozer, Richard [14 ]
D'Souza, David P. [15 ]
Chalchal, Haji [16 ]
Spadafora, Silvana [17 ]
Stearns, Vered [18 ]
Perez, Edith A. [7 ,19 ]
Gelmon, Karen A. [20 ]
Whelan, Timothy J. [14 ]
Elliott, Catherine [6 ]
Shepherd, Lois E. [6 ]
Chen, Bingshu E. [6 ]
Taylor, Karen J. [5 ]
机构
[1] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[2] Ontario Inst Canc Res, Toronto, ON, Canada
[3] Univ Toronto, Toronto, ON, Canada
[4] Queens Univ, Kingston, ON, Canada
[5] Univ Edinburgh, Edinburgh, Scotland
[6] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[7] Harvard Univ, Boston, MA USA
[8] Mayo Clin, Rochester, MN USA
[9] Progendis, Gaithersburg, MD USA
[10] Caris Life Sci, Irving, TX USA
[11] Cleveland Clin, Cleveland, OH USA
[12] Inselspital Bern, Bern, Switzerland
[13] Indiana Sch Med, South Bend, IN USA
[14] McMaster Univ, Hamilton, ON, Canada
[15] London Reg Hlth Sci Ctr, London, ON, Canada
[16] Alan Blair Canc Ctr, Regina, SK, Canada
[17] Algoma Reg Canc Ctr, Sault Ste Marie, ON, Canada
[18] Weill Cornell Med, New York, NY USA
[19] Mayo Clin, Redwood City, CA USA
[20] Univ British Columbia, Vancouver, BC, Canada
关键词
ER; EXPRESSION; TAMOXIFEN; WOMEN; PR;
D O I
10.1200/JCO.24.00835
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE ASCO/College of American Pathologists guidelines recommend reporting estrogen receptor (ER) and progesterone receptor (PgR) as positive with (1%-100%) staining. Statistically standardized quantitated positivity could indicate differential associations of positivity with breast cancer outcomes. METHODS MA.27 (ClinicalTrials.gov identifier: NCT00066573) was a phase III adjuvant trial of exemestane versus anastrozole in postmenopausal women with early-stage breast cancer. Immunochemistry ER and PgR HSCORE and % positivity (%+) were centrally assessed by machine image quantitation and statistically standardized to mean 0 and standard deviation (SD) 1 after Box-Cox variance stabilization transformations of square for ER; for PgR, (1) natural logarithm (0.1 added to 0 HSCOREs and 0%+) and (2) square root. Our primary end point was MA.27 distant disease-free survival (DDFS) at a median 4.1-year follow-up, and secondary end point was event-free survival (EFS). Univariate survival with cut points at SDs about a mean of 0 (<=-1; (-1, 0]; (0, 1]; >1) was described with Kaplan-Meier plots and examined with Wilcoxon (Peto-Prentice) test statistic. Adjusted Cox multivariable regressions had two-sided Wald tests and nominal significance P < .05. RESULTS Of 7,576 women accrued, 3,048 women's tumors had machine-quantitated image analysis results: 2,900 (95%) for ER, 2,726 (89%) for PgR, and 2,582 (85% of 3,048) with both ER and PgR. Higher statistically standardized ER and PgR HSCORE and %+ were associated with better univariate DDFS and EFS (P < .001). In multivariable assessments, ER HSCORE and %+ were not significantly associated (P = .52-.88) with DDFS in models with PgR, whereas higher PgR HSCORE and %+ were significantly associated with better DDFS (P = .001) in models with ER. CONCLUSION Adjunctive statistical standardization differentiated quantitated levels of ER and PgR. Patients with higher ER- and PgR-standardized units had superior DDFS compared with those with HSCOREs and %+ <=-1.
引用
收藏
页码:2887 / 2898
页数:19
相关论文
共 16 条
[1]   Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update [J].
Allison, Kimberly H. ;
Hammond, M. Elizabeth H. ;
Dowsett, Mitchell ;
McKernin, Shannon E. ;
Carey, Lisa A. ;
Fitzgibbons, Patrick L. ;
Hayes, Daniel F. ;
Lakhani, Sunil R. ;
Chavez-MacGregor, Mariana ;
Perlmutter, Jane ;
Perou, Charles M. ;
Regan, Meredith M. ;
Rimm, David L. ;
Symmans, W. Fraser ;
Torlakovic, Emina E. ;
Varella, Leticia ;
Viale, Giuseppe ;
Weisberg, Tracey F. ;
McShane, Lisa M. ;
Wolff, Antonio C. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) :1346-+
[2]   Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial [J].
Bartlett, John M. S. ;
Brookes, Cassandra L. ;
Robson, Tammy ;
van de Velde, Cornelis J. H. ;
Billingham, Lucinda J. ;
Campbell, Fiona M. ;
Grant, Margaret ;
Hasenburg, Annette ;
Hille, Elysee T. M. ;
Kay, Charlene ;
Kieback, Dirk G. ;
Putter, Hein ;
Markopoulos, Christos ;
Kranenbarg, Elma Meershoek-Klein ;
Mallon, Elizabeth A. ;
Dirix, Luc ;
Seynaeve, Caroline ;
Rea, Daniel .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (12) :1531-1538
[3]  
BMDP Statistical Software, 2009, WINDOWS VERSION 81 S
[4]   AN ANALYSIS OF TRANSFORMATIONS [J].
BOX, GEP ;
COX, DR .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1964, 26 (02) :211-252
[5]   THE STANDARDIZATION OF ESTROGEN-RECEPTORS [J].
CHAPMAN, JAW ;
MOBBS, BG ;
HANNA, WM ;
SAWKA, CA ;
PRITCHARD, KI ;
LICKLEY, HL ;
TRUDEAU, ME ;
RYAN, ED ;
OOI, TC ;
SUTHERLAND, DJA ;
TUSTANOFF, ER ;
MCCREADY, DR .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1993, 45 (05) :367-373
[6]   Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14 [J].
Chapman, Judith-Anne W. ;
Sgroi, Dennis C. ;
Goss, Paul E. ;
Zarella, Elizabeth ;
Binns, Shemeica ;
Zhang, Yi ;
Schnabel, Catherine A. ;
Erlander, Mark G. ;
Pritchard, Kathleen I. ;
Han, Lei ;
Badovinac-Crnjevic, Tanja ;
Shepherd, Lois E. ;
Pollak, Michael N. .
BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (01) :101-108
[7]   Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27 [J].
Chapman, Judith-Anne W. ;
Shepherd, Lois E. ;
Ingle, James N. ;
Muss, Hyman B. ;
Pritchard, Kathleen I. ;
Gelmon, Karen A. ;
Whelan, Timothy J. ;
Elliott, Catherine ;
Goss, Paul E. .
BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (02) :343-349
[8]   Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort [J].
Chapman, Judith-Anne W. ;
Nielsen, Torsten O. ;
Ellis, Matthew J. ;
Bernard, Phillip ;
Chia, Stephen ;
Gelmon, Karen A. ;
Pritchard, Kathleen I. ;
Le Maitre, Aurelie ;
Goss, Paul E. ;
Leung, Samuel ;
Shepherd, Lois E. ;
Bramwell, Vivien H. C. .
BREAST CANCER RESEARCH, 2013, 15 (04)
[9]   An investigation of cut points for primary breast cancer oestrogen and progesterone receptor assays [J].
Chapman, JW ;
Mobbs, BG ;
McCready, DR ;
Lickley, HLA ;
Trudeau, ME ;
Hanna, W ;
Kahn, HJ ;
Sawka, CA ;
Fish, EB ;
Pritchard, KI .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1996, 57 (5-6) :323-328
[10]  
Chapman JW., 2000, C T STER R, V3, P39